Strongyloidiasis overview: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(44 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Strongyloidiasis}}
{{Strongyloidiasis}}
{{CMG}} ; {{AE}} {{ADG}}
{{CMG}}; {{AE}} {{ADG}}
==Overview==
==Overview==
[[Strongyloidiasis]] is a [[List of human parasitic diseases|human parasitic disease]] caused by the [[nematode]] ([[roundworm]]) ''[[Strongyloides stercoralis]]'', or sometimes ''S. fülleborni''. The primary mode of infection is through contact with soil that is contaminated with free-living larvae. It can cause a variety of symptoms, most commonly [[Skin lesions|skin lesions,]] [[abdominal pain]], [[diarrhea]] and [[weight loss#Unintentional weight loss|weight loss]]. In some people, particularly those who require [[corticosteroid]]s or other [[Immunosuppressive therapy|immunosuppressive medication]], ''[[Strongyloidiasis|strongyloides]]'' can cause a hyperinfection syndrome that can lead to death if untreated. The disease may be complicated by disseminated strongyloidiasis (especially in [[immunosuppressed]] patients), [[eosinophilic pneumonia]], and [[malnutrition]]. The diagnosis is made by blood and [[Stool test|stool tests]]. The drug [[ivermectin]] is the drug of choice in the treatment of [[strongyloidiasis]].
Strongyloidiasis is an [[infection]] caused by a [[roundworm]] ([[nematode]]), ''[[Strongyloides stercoralis]]''. Transmission occurs predominantly in tropical and subtropical areas but can also be found in countries with temperate environments including the southeastern U.S. [[Infection]] is contracted via direct contact with contaminated soil during [[Agricultural chemistry|agricultural]], domestic, and recreational activities. ''[[Strongyloides stercoralis|S stercoralis]]'' in humans usually produces an [[asymptomatic]] [[Chronic|chronic infection]] of the [[gastrointestinal tract]] that can remain undetected for several decades. Usually there are no unique clinical symptoms to suggest [[infection]], although [[Bloating|abdominal bloating]] and [[eosinophilia]] are common in many infected patients. In some patients a disseminated or hyperinfection syndrome can develop with the dissemination of larvae to extra-intestinal organs, and that can result in mortality rates exceeding 90%. Risk factors and predisposing conditions include [[Immunosuppressive therapy|immunosuppressive therapies]] with [[corticosteroids]] and other medications, [[HTLV-1|HTLV-1 infection]], [[organ transplantation]], [[immune reconstitution syndrome]], hematologic malignancies ([[lymphoma]]), [[tuberculosis]], and [[malnutrition]]. Diagnosis is generally made by the [[Stool examination|detection of larvae in the stool]]. [[Ivermectin]], [[thiabendazole]], and [[albendazole]] are the most effective medicines for treating the infection. Excellent recovery after treatment should be expected in [[immunocompetent]] patients.


==Historical Perspective==
==Historical Perspective==
The [[disease]] was first discovered in 1876 by the French physician Louis Alexis Normand working in the naval hospital in Toulon; he identified the adult worms and sent them to Arthur Réné Jean Baptiste Bavay, chief health inspector, who observed that the worms were the adult forms of the larvae found in [[stool]]. In 1883 the German parasitologist Rudolf Leuckart made initial observations on the life cycle of [[Parasites|parasite]]. Belgian physician Paul Van Durme described the mode of infection through the skin. The German parasitologist Friedrich Fülleborn described [[autoinfection]] and the way by which strongyloidiasis involves the [[intestine]]. Strongyloidiasis was investigated further during the 1940s as persons who had acquired the infection abroad and then received [[immunosuppression]] developed hyper infestation syndrome.<ref name="Cox">{{cite journal | author=Cox FE | title=History of Human Parasitology | journal=Clin. Microbiol. Rev. | volume=15 | issue=4 | pages=595–612 | pmid=12364371 | doi=10.1128/CMR.15.4.595-612.2002 | pmc=126866 | url=http://cmr.asm.org/cgi/content/full/15/4/595}}</ref>
''[[Strongyloides]]'' was first discovered in 1876 by the French physician Louis Alexis Normand while working in the naval hospital in Toulon; he identified the adult worms and sent them to Arthur Réné Jean Baptiste Bavay, chief health inspector, who observed that the worms were the adult forms of the larvae found in [[stool]]. In 1883, the German parasitologist Rudolf Leuckart made initial observations on the life cycle of [[Parasites|parasite]]. Belgian physician Paul Van Durme described the mode of infection through the skin. The German parasitologist Friedrich Fülleborn described [[autoinfection]] and the mechanism by which strongyloidiasis involves the [[intestine]]. Strongyloidiasis was investigated further during the 1940s, as persons who had acquired the infection abroad and then received [[immunosuppression]] developed hyper-infestation syndrome.
 
==Classification==
Strongyloidiasis may be classified as acute or chronic based on the duration of symptoms and as hyper infection syndrome or disseminated strongyloidiasis based on the organ system involvement.


==Pathophysiology==
==Pathophysiology==
[[Strongyloides]] is classified as a soil-transmitted [[helminth]]. The primary mode of infection is through contact with soil that is contaminated with free-living larvae. When the larvae come in contact with skin, they are able to penetrate it and migrate through the body, eventually finding their way to the [[small intestine]] where they burrow and lay their eggs. Unlike other soil-transmitted [[helminths]] such as [[hookworm]] and [[whipworm]], whose eggs do not hatch until they are outside the body, the eggs of [[Strongyloidiasis|Strongyloides]] hatch into larvae in the [[intestine]]. Most of these larvae will be excreted in the stool, but some of the larvae may molt and immediately re-infect the host either by burrowing into the [[intestinal]] wall or by penetrating the [[Perianal abscess|perianal]] [[skin]]. This characteristic of [[Strongyloidiasis|Strongyloides]] is termed auto-infection. The significance of auto-infection is that if left untreated, persons may remain infected throughout their lifetime.<ref name="pmid27213420">{{cite journal |vauthors=Beknazarova M, Whiley H, Ross K |title=Strongyloidiasis: A Disease of Socioeconomic Disadvantage |journal=Int J Environ Res Public Health |volume=13 |issue=5 |pages= |year=2016 |pmid=27213420 |pmc=4881142 |doi=10.3390/ijerph13050517 |url=}}</ref><ref name="pmid19334396">{{cite journal |vauthors=Ardiç N |title=[An overview of Strongyloides stercoralis and its infections] |language=Turkish |journal=Mikrobiyol Bul |volume=43 |issue=1 |pages=169–77 |year=2009 |pmid=19334396 |doi= |url=}}</ref><ref name="pmid14726461">{{cite journal |vauthors=Keiser PB, Nutman TB |title=Strongyloides stercoralis in the Immunocompromised Population |journal=Clin. Microbiol. Rev. |volume=17 |issue=1 |pages=208–17 |year=2004 |pmid=14726461 |pmc=321465 |doi= |url=}}</ref><ref name="urlCDC - Strongyloides - Biology">{{cite web |url=https://www.cdc.gov/parasites/strongyloides/biology.html |title=CDC - Strongyloides - Biology |format= |work= |accessdate=}}</ref>
[[Strongyloides|''Strongyloides'']] is a soil-transmitted [[helminth]]. The principal definitive hosts of ''[[Strongyloides stercoralis|S stercoralis]]'' are humans, but [[infection]] in dogs can also occur. [[Infection]] is contracted via direct contact with contaminated soil during agricultural, domestic, and recreational activities. Filariform larvae penetrate the [[skin]] and enter a [[venous]] or [[Lymphatic system|lymphatic]] vessel. These larvae then migrate to the [[lungs]], where they break out of the [[capillaries]] into the [[alveoli]] and move to the [[trachea]] as they mature. Eventually these larvae gets coughed up and swallowed. [[Parthenogenesis|Parthenogenetic]] female worms reside in the [[lamina propria]] of the [[duodenum]] and the proximal [[jejunum]], where they lay eggs. The eggs hatch into rhabditiform larvae. These larvae migrate into the [[Lumen|intestinal lumen]] and ultimately exit the body with the [[feces]]. The free-living rhabditiform larvae may either directly molt into infective (parasitic) filariform larvae that are capable of penetrating the [[skin]] of a suitable host or shift to a free-living cycle. In this latter indirect (heterogonic) cycle, molts result in the development of adult male and female worms that mate and produce a generation of offspring whose filariform stage will have the ability to re-enter parasitic life. A small percentage of the rhabditiform larvae molt within the host's [[intestine]] into the filariform stage. These tissue-penetrating infective larvae may penetrate the [[Colon (anatomy)|colonic wall]] or the perianal skin, completing an internal cycle, and maturing into adult females in the [[small intestine]]. This process is known as [[autoinfection]] and may be the mechanism by which ''[[Strongyloides stercoralis|S stercoralis]]'' can persist indefinitely in infected hosts. This is a unique characteristic of ''[[Strongyloides stercoralis|S stercoralis]]''.


==Causes==
==Causes==
Strongyloidiasis is a [[List of human parasitic diseases|human parasitic disease]] caused by the [[nematode]] ([[roundworm]]) ''[[Strongyloides stercoralis]]'' or sometimes <nowiki/>S. fülleborni.
Strongyloidiasis is a [[List of human parasitic diseases|human parasitic disease]] caused by the [[nematode]] ([[roundworm]]) ''[[Strongyloides stercoralis]]'' or sometimes <nowiki/>''S. fülleborni''.


==Differentiating Strongyloidiasis from other Diseases==
==Differentiating Strongyloidiasis from other Diseases==
Strongyloidiasis can mimic other [[worm]] [[infections]] like ''[[Ascaris lumbricoides]]'', ''[[Trichuris trichiura]]'', [[Hookworm Infection|hookworm infections]] (''[[Necator americanus]]'' and ''[[Ancylostoma duodenale]]''), ''[[Enterobius vermicularis]]'' ([[pinworm]]) and also gastrointestinal pathologies such as [[peptic ulcer disease]], [[intussusception]] in children, [[Choledocholithiasis|bile duct stone]], etc.<ref name="Principles and Practice">Durand, Marlene (2015). "Chapter 288:Intestinal Nematodes (Roundworms)". Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases Updated Edition, Eighth Edition. Elsevier. pp. 3199–3207. ISBN 978-1-4557-4801-3.</ref><ref name="Murray and Nadel's Textbook of Respiratory Medicine">{{cite book |last1=Kim |first1=Kami |last2=Weiss |first2=Louis |last3=Tanowitz |first3=Herbert |title=Murray and Nadel's Textbook of Respiratory Medicine Sixth Edition |publisher=Elsevier |date=2016 |pages=682-698 |chapter=Chapter 39:Parasitic Infections |isbn=978-1-4557-3383-5}}</ref><ref name="pmid25121962">{{cite journal |vauthors=Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X |title=Strongyloidiasis--an insight into its global prevalence and management |journal=PLoS Negl Trop Dis |volume=8 |issue=8 |pages=e3018 |year=2014 |pmid=25121962 |pmc=4133206 |doi=10.1371/journal.pntd.0003018 |url=}}</ref>
Strongyloidiasis can mimic other [[worm]] [[infections]] like ''[[Ascaris lumbricoides]]'', ''[[Trichuris trichiura]]'', [[Hookworm Infection|hookworm infections]] (''[[Necator americanus]]'' and ''[[Ancylostoma duodenale]]''), ''[[Enterobius vermicularis]]'' ([[pinworm]]) and gastrointestinal pathologies such as [[peptic ulcer disease]], [[intussusception]] in children, and [[Choledocholithiasis|bile duct stone]].


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The global [[prevalence]] of [[Strongyloides]] is unknown, but experts estimate that there are between 30–100 million infected persons worldwide, mainly in [[Tropical medicine|tropical]] and subtropical countries and is more common in the [[pediatric]] age group (ages 2-10 years).<ref name="urlCDC - Strongyloides - Epidemiology & Risk Factors">{{cite web |url=https://www.cdc.gov/parasites/strongyloides/epi.html |title=CDC - Strongyloides - Epidemiology & Risk Factors |format= |work= |accessdate=}}</ref><ref name="pmid25121962">{{cite journal |vauthors=Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X |title=Strongyloidiasis--an insight into its global prevalence and management |journal=PLoS Negl Trop Dis |volume=8 |issue=8 |pages=e3018 |year=2014 |pmid=25121962 |pmc=4133206 |doi=10.1371/journal.pntd.0003018 |url=}}</ref><ref name="pmid23875033">{{cite journal |vauthors=Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, Vounatsou P, Odermatt P |title=Strongyloides stercoralis: Global Distribution and Risk Factors |journal=PLoS Negl Trop Dis |volume=7 |issue=7 |pages=e2288 |year=2013 |pmid=23875033 |pmc=3708837 |doi=10.1371/journal.pntd.0002288 |url=}}</ref>
The global [[prevalence]] of [[Strongyloides|''Strongyloides'']] is unknown, but recent studies estimate that there are between 30–100 million infected persons worldwide, mainly in [[Tropical medicine|tropical]] and subtropical countries. Strongyloidiasis is more common in the [[pediatric]] age group (ages 2-10 years).


==Risk Factors==
==Risk Factors==
[[Strongyloides]] is found more frequently in the socioeconomically disadvantaged, institutionalized populations, and in rural areas. Activities that increase contact with the soil increase the risk of becoming infected, such as walking with bare feet or contact with human waste or sewage. Occupations that increase contact with contaminated soil such as farming and coal mining, and history of infection with [[Human T-lymphotropic virus|Human T-Cell Lymphotropic Virus-1]] ([[HTLV-1]]) also increase risk of infection.<ref name="pmid26925367">{{cite journal |vauthors=Ostera G, Blum J |title=Strongyloidiasis: Risk and Healthcare Access for Latin American Immigrants Living in the United States |journal=Curr Trop Med Rep |volume=3 |issue= |pages=1–3 |year=2016 |pmid=26925367 |pmc=4757600 |doi=10.1007/s40475-016-0065-3 |url=}}</ref><ref name="urlCDC - Strongyloides - Epidemiology & Risk Factors">{{cite web |url=https://www.cdc.gov/parasites/strongyloides/epi.html |title=CDC - Strongyloides - Epidemiology & Risk Factors |format= |work= |accessdate=}}</ref>
Common risk factors in the development of strongyloidiasis include [[Immunosuppressive therapy|immunosuppressive therapies]] with [[corticosteroids]] and other medications, [[HTLV-1|HTLV-1 infection]], [[organ transplantation]], [[immune reconstitution syndrome]], hematologic malignancies (especially [[lymphoma]]), [[tuberculosis]], and [[malnutrition]]


==Natural history, Complications and Prognosis==
==Screening==
If [[Strongyloides]] is left untreated, the infection can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis, especially in patients with [[HIV]] or an otherwise weakened immune system, [[eosinophilic pneumonia]], and [[malnutrition]] due to problems absorbing nutrients from the gastrointestinal tract ([[malabsorption]]). With appropriate treatment, people should make a full recovery. Oftentimes, treatment needs to be repeated. [[Infections]] that are severe or widespread often have a poor outcome, especially in people with a weakened immune system.
Most fatal infections caused by ''[[Strongyloides stercoralis|S.stercoralis]]'' can be prevented by early detection and treatment of asymptomatic chronic infections. Screening is highly recommended to detect latent ''[[Strongyloides stercoralis|S.stercoralis]]'' infection before the start of [[chemotherapy]] or [[immunosuppression]]/[[steroid therapy]] in patients at risk. Repeated [[stool examination]] for [[ova]] and [[parasites]] or agar culture of stool may be the most appropriate approach.
 
==Natural history, Complications, and Prognosis==
If strongyloidiasis is left untreated, the infection can disseminate and transform into hyper-infection syndrome which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with [[HIV]] or other immunocompromised conditions ), [[eosinophilic pneumonia]], [[malnutrition]], and [[malabsorption]]. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. [[Infections]] that are severe or widespread often have a poor outcome, especially in people with a [[Suppressed immune systems|suppressed immune system]].


==Diagnosis==
==Diagnosis==
===History and symptoms===
===History and symptoms===
Strongyloides infection occurs in five forms. On acquiring the infection, there may be respiratory symptoms ([[Löffler's syndrome]]). The infection may then become chronic with mainly digestive symptoms. On reinfection (when larvae migrate through the body), there may be [[respiratory]], [[skin]] and [[Digestive system|digestive]] symptoms. Finally, the hyperinfection syndrome causes symptoms in many organ systems, including the [[central nervous system]].<ref name="Montes">{{cite journal | author=Montes M, Sawhney C, Barros N | title=Strongyloides stercoralis: there but not seen | journal=Curr Opin Infect Dis| volume=23 | issue=5 | pages=500–4 | pmid=20733481 | pmc=2948977 | doi=10.1097/QCO.0b013e32833df718}}</ref><ref name="Marcos">{{cite journal | author=Marcos LA, Terashima A, Dupont HL, Gotuzzo E | title=Strongyloides hyperinfection syndrome: an emerging global infectious disease | journal=Trans R Soc Trop Med Hyg | volume=102 | issue=4 | pages=314–8 | pmid=18321548 | doi=10.1016/j.trstmh.2008.01.020}}</ref>
[[Strongyloides|''Strongyloides'']] infection can present in various forms. The majority of people infected with ''[[Strongyloides]]'' are asymptomatic. The symptomatic spectrum of strongyloidiasis ranges from subclinical in acute and chronic infection to severe and fatal in hyper infection syndrome. On acquiring the infection, there may be respiratory symptoms ([[Löffler's syndrome]]). The infection may progress to chronic stage with mainly [[Gastrointestinal tract|digestive symptoms]]. On reinfection there may be [[respiratory]], [[skin]], and [[Digestive system|digestive]] symptoms. Finally, hyper infection syndrome sets in and cause symptoms in many organ systems, including the [[central nervous system]].


===Physical examination===
===Physical examination===
The physical examination findings in strongyloidiasis vary and are usually dependent on the worm burden and the involved organ.<ref name="pmid17940124">{{cite journal |vauthors=Segarra-Newnham M |title=Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection |journal=Ann Pharmacother |volume=41 |issue=12 |pages=1992–2001 |year=2007 |pmid=17940124 |doi=10.1345/aph.1K302 |url=}}</ref>
The physical examination findings in strongyloidiasis vary and are usually dependent on the worm burden and the involved organ.


===Laboratory findings===
===Laboratory findings===
The gold standard for the diagnosis of strongyloides is serial [[stool examination]]. [[Duodenal]] aspirate is more [[Sensitivity (tests)|sensitive]] than [[stool examination]]. [[Duodenal]] [[biopsy]] may reveal [[parasites]] in the gastric crypts, [[duodenal glands]], or [[Eosinophilic enteritis|eosinophilic]] infiltration in the [[lamina propria]]. In disseminated cases of strongyloidiasis, larvae can be detected in [[sputum]] by simple wet-mount of [[bronchoalveolar lavage]] ([[BAL]]). [[Immunodiagnostics|Immunodiagnostic]] tests for strongyloidiasis are indicated when the infection is suspected and the organism cannot be demonstrated by [[duodenal]] aspiration, string tests, or by repeated examinations of [[stool]]. [[Enzyme immunoassay]] ([[EIA]]) is currently recommended because of its greater [[Sensitivity (tests)|sensitivity]] (90%). Cross-reactions in patients with [[filariasis]] and some other [[nematode]] [[infections]] can occur. Antibody test results cannot be used to differentiate between the past and current infection.<ref name="pmid28210503">{{cite journal |vauthors=Mendes T, Minori K, Ueta M, Miguel DC, Allegretti SM |title=Strongyloidiasis Current Status with Emphasis in Diagnosis and Drug Research |journal=J Parasitol Res |volume=2017 |issue= |pages=5056314 |year=2017 |pmid=28210503 |pmc=5292188 |doi=10.1155/2017/5056314 |url=}}</ref><ref name="pmid27213420">{{cite journal |vauthors=Beknazarova M, Whiley H, Ross K |title=Strongyloidiasis: A Disease of Socioeconomic Disadvantage |journal=Int J Environ Res Public Health |volume=13 |issue=5 |pages= |year=2016 |pmid=27213420 |pmc=4881142 |doi=10.3390/ijerph13050517 |url=}}</ref><ref name="pmid11528578">{{cite journal |vauthors=Siddiqui AA, Berk SL |title=Diagnosis of Strongyloides stercoralis infection |journal=Clin. Infect. Dis. |volume=33 |issue=7 |pages=1040–7 |year=2001 |pmid=11528578 |doi=10.1086/322707 |url=}}</ref>
The diagnosis of strongyloidiasis is made by presence of clinical signs and symptoms, [[eosinophilia]], and positive serological findings. Definitive diagnosis of strongyloidiasis is generally made by the [[Stool examination|detection of larvae in the stool]]. [[Sputum culture|Sputum examination]] may rarely be used to identify organisms in cases of hyperinfection. [[Agar]] tracking (detection of larval tracks on [[Agar|agar culture]] plates) has been shown to be more [[Sensitivity (tests)|sensitive]] than the conventional [[stool examination]]. However, [[agar]] tracking is usually unavailable on a routine basis in clinical microbiology laboratories. [[Immunodiagnostics|Immunodiagnostic tests]] for [[strongyloidiasis]] are indicated when the [[infection]] is suspected and the organism cannot be demonstrated by repeated examinations of [[stool]]. [[Enzyme immunoassay]] ([[EIA]]) is currently recommended because of its greater [[sensitivity]] (90%). [[Antibody]] test results cannot be used to differentiate between the past and current infection. In disseminated cases of [[strongyloidiasis]], larvae can be detected in [[sputum]] by simple wet-mount in fluid from a [[bronchoalveolar lavage]] ([[BAL]]).


===Chest and Abdominal Xrays===
===X-ray===
Radiographs can be useful investigations in the diagnosis of [[ascariasis]]. A chest x-ray can reveal varying sizes of oval or round infiltrates ([[Löffler's syndrome]]). Plain abdominal radiographs and contrast studies may reveal worm masses in bowel loops.<ref name="pmid17940124">{{cite journal |vauthors=Segarra-Newnham M |title=Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection |journal=Ann Pharmacother |volume=41 |issue=12 |pages=1992–2001 |year=2007 |pmid=17940124 |doi=10.1345/aph.1K302 |url=}}</ref>
X rays can be helpful in the diagnosis of strongyloidiasis. Radiographic findings are variable, depending upon the stage and extent of infection which includes pulmonary infiltrates, when present, may be alveolar or interstitial, diffuse or focal, uni- or bilateral. [[Lung consolidation]], occasional [[cavitation]], and even [[Abscess of lung|abscess]] formation can also be found. Plain abdominal radiographs and contrast studies can reveal worm masses in bowel loops. Chest radiographs are explained by pulmonary migration of the [[parasites]] and by different types of [[bacterial]] [[super-infection]], particularly [[gram-negative bacilli]].


===CT===
===CT===
There are no specific CT findings associated with strongyloidiasis but in cases of abdominal obstruction due to worm burden CT can demonstrate collapsed loops of bowel distally and radial distribution of several dilated, fluid-filled bowel loops
There are no specific CT findings associated with strongyloidiasis. However, in cases of abdominal obstruction due to worm burden, CT can demonstrate collapsed loops of the bowel [[distal|distally]] and radial distribution of several dilated, fluid-filled bowel loops.
 
===MRI===
There are no specific MRI findings associated with strongyloidiasis.


===Ultrasound===
===Ultrasound===
Line 48: Line 57:


===Other diagnostic tests===
===Other diagnostic tests===
Upper and lower GI [[endoscopy]], skin biopsy, and [[BAL]] fluid examination are some other diagnostic tests that are employed in diagnosing strongyloidiasis when there is a negative stool exam.
Upper and lower [[Gastrointestinal tract|GI]] [[endoscopy]], [[skin biopsy]], and [[BAL]] fluid examination are some other diagnostic tests that are employed in diagnosing strongyloidiasis when there is a negative stool exam.


==Treatment==
==Treatment==


===Medical Therapy===
===Medical Therapy===
 
[[Ivermectin]], [[thiabendazole]], and [[albendazole]] are the most effective medicines for treating strongyloidiasis infection. [[Ivermectin]] is the drug of choice, and [[albendazole]] is considered the least effective. [[Thiabendazole]] is not generally used in the U.S. due to adverse events, but it is still used in other countries. All patients with strongyloidiasis (even asymptomatic patients) require treatment. Complete obstruction with inadequate decompression, lack of response within an interval of 24-48 hrs, [[volvulus]], [[intussusception]], or [[Gastrointestinal perforation|perforation]] should be managed surgically.
The drug of choice for the treatment of uncomplicated strongyloidiasis is [[ivermectin]] with [[albendazole]] as the alternative. All patients who are at risk of disseminated strongyloidiasis should be hospitalized.<ref name="pmid17940124">{{cite journal |vauthors=Segarra-Newnham M |title=Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection |journal=Ann Pharmacother |volume=41 |issue=12 |pages=1992–2001 |year=2007 |pmid=17940124 |doi=10.1345/aph.1K302 |url=}}</ref><ref>http://www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm</ref>


===Surgery===
===Surgery===
Strongyloidiasis is usually managed conservatively with medical therapy but [[surgery]] may be indicated when medical management fails or complications arise.
Strongyloidiasis is usually managed with medical therapy. However, [[surgery]] may be indicated when medical management fails or complications arise.


===Primary Prevention===
===Primary Prevention===
The prevention of strongyloidiasis is best achieved through improvements in personal hygiene and environmental sanitation.
The prevention of strongyloidiasis is best achieved through improvements in personal hygiene and environmental sanitation.
===Secondary Prevention===
===Secondary Prevention===
Secondary preventive measures of strongyloidiasis are similar as of [[Strongyloidiasis primary prevention|primary preventive measures]].<ref name="pmid17940124">{{cite journal |vauthors=Segarra-Newnham M |title=Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection |journal=Ann Pharmacother |volume=41 |issue=12 |pages=1992–2001 |year=2007 |pmid=17940124 |doi=10.1345/aph.1K302 |url=}}</ref>
Secondary preventive measures of strongyloidiasis are similar to [[Strongyloidiasis primary prevention|primary preventive measures]].


==References==
==References==


{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}


[[Category:Disease]]
[[Category:Disease]]
[[Category:Emergency mdicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
 
[[Category:Gastroenterology]]
{{WH}}
[[Category:Dermatology]]
{{WS}}
[[Category:Neurology]]
[[Category:Pulmonology]]

Latest revision as of 00:19, 30 July 2020

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis overview

CDC on Strongyloidiasis overview

Strongyloidiasis overview in the news

Blogs on Strongyloidiasis overview

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Strongyloidiasis is an infection caused by a roundworm (nematode), Strongyloides stercoralis. Transmission occurs predominantly in tropical and subtropical areas but can also be found in countries with temperate environments including the southeastern U.S. Infection is contracted via direct contact with contaminated soil during agricultural, domestic, and recreational activities. S stercoralis in humans usually produces an asymptomatic chronic infection of the gastrointestinal tract that can remain undetected for several decades. Usually there are no unique clinical symptoms to suggest infection, although abdominal bloating and eosinophilia are common in many infected patients. In some patients a disseminated or hyperinfection syndrome can develop with the dissemination of larvae to extra-intestinal organs, and that can result in mortality rates exceeding 90%. Risk factors and predisposing conditions include immunosuppressive therapies with corticosteroids and other medications, HTLV-1 infection, organ transplantation, immune reconstitution syndrome, hematologic malignancies (lymphoma), tuberculosis, and malnutrition. Diagnosis is generally made by the detection of larvae in the stool. Ivermectin, thiabendazole, and albendazole are the most effective medicines for treating the infection. Excellent recovery after treatment should be expected in immunocompetent patients.

Historical Perspective

Strongyloides was first discovered in 1876 by the French physician Louis Alexis Normand while working in the naval hospital in Toulon; he identified the adult worms and sent them to Arthur Réné Jean Baptiste Bavay, chief health inspector, who observed that the worms were the adult forms of the larvae found in stool. In 1883, the German parasitologist Rudolf Leuckart made initial observations on the life cycle of parasite. Belgian physician Paul Van Durme described the mode of infection through the skin. The German parasitologist Friedrich Fülleborn described autoinfection and the mechanism by which strongyloidiasis involves the intestine. Strongyloidiasis was investigated further during the 1940s, as persons who had acquired the infection abroad and then received immunosuppression developed hyper-infestation syndrome.

Classification

Strongyloidiasis may be classified as acute or chronic based on the duration of symptoms and as hyper infection syndrome or disseminated strongyloidiasis based on the organ system involvement.

Pathophysiology

Strongyloides is a soil-transmitted helminth. The principal definitive hosts of S stercoralis are humans, but infection in dogs can also occur. Infection is contracted via direct contact with contaminated soil during agricultural, domestic, and recreational activities. Filariform larvae penetrate the skin and enter a venous or lymphatic vessel. These larvae then migrate to the lungs, where they break out of the capillaries into the alveoli and move to the trachea as they mature. Eventually these larvae gets coughed up and swallowed. Parthenogenetic female worms reside in the lamina propria of the duodenum and the proximal jejunum, where they lay eggs. The eggs hatch into rhabditiform larvae. These larvae migrate into the intestinal lumen and ultimately exit the body with the feces. The free-living rhabditiform larvae may either directly molt into infective (parasitic) filariform larvae that are capable of penetrating the skin of a suitable host or shift to a free-living cycle. In this latter indirect (heterogonic) cycle, molts result in the development of adult male and female worms that mate and produce a generation of offspring whose filariform stage will have the ability to re-enter parasitic life. A small percentage of the rhabditiform larvae molt within the host's intestine into the filariform stage. These tissue-penetrating infective larvae may penetrate the colonic wall or the perianal skin, completing an internal cycle, and maturing into adult females in the small intestine. This process is known as autoinfection and may be the mechanism by which S stercoralis can persist indefinitely in infected hosts. This is a unique characteristic of S stercoralis.

Causes

Strongyloidiasis is a human parasitic disease caused by the nematode (roundworm) Strongyloides stercoralis or sometimes S. fülleborni.

Differentiating Strongyloidiasis from other Diseases

Strongyloidiasis can mimic other worm infections like Ascaris lumbricoides, Trichuris trichiura, hookworm infections (Necator americanus and Ancylostoma duodenale), Enterobius vermicularis (pinworm) and gastrointestinal pathologies such as peptic ulcer disease, intussusception in children, and bile duct stone.

Epidemiology and Demographics

The global prevalence of Strongyloides is unknown, but recent studies estimate that there are between 30–100 million infected persons worldwide, mainly in tropical and subtropical countries. Strongyloidiasis is more common in the pediatric age group (ages 2-10 years).

Risk Factors

Common risk factors in the development of strongyloidiasis include immunosuppressive therapies with corticosteroids and other medications, HTLV-1 infection, organ transplantation, immune reconstitution syndrome, hematologic malignancies (especially lymphoma), tuberculosis, and malnutrition

Screening

Most fatal infections caused by S.stercoralis can be prevented by early detection and treatment of asymptomatic chronic infections. Screening is highly recommended to detect latent S.stercoralis infection before the start of chemotherapy or immunosuppression/steroid therapy in patients at risk. Repeated stool examination for ova and parasites or agar culture of stool may be the most appropriate approach.

Natural history, Complications, and Prognosis

If strongyloidiasis is left untreated, the infection can disseminate and transform into hyper-infection syndrome which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with HIV or other immunocompromised conditions ), eosinophilic pneumonia, malnutrition, and malabsorption. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. Infections that are severe or widespread often have a poor outcome, especially in people with a suppressed immune system.

Diagnosis

History and symptoms

Strongyloides infection can present in various forms. The majority of people infected with Strongyloides are asymptomatic. The symptomatic spectrum of strongyloidiasis ranges from subclinical in acute and chronic infection to severe and fatal in hyper infection syndrome. On acquiring the infection, there may be respiratory symptoms (Löffler's syndrome). The infection may progress to chronic stage with mainly digestive symptoms. On reinfection there may be respiratory, skin, and digestive symptoms. Finally, hyper infection syndrome sets in and cause symptoms in many organ systems, including the central nervous system.

Physical examination

The physical examination findings in strongyloidiasis vary and are usually dependent on the worm burden and the involved organ.

Laboratory findings

The diagnosis of strongyloidiasis is made by presence of clinical signs and symptoms, eosinophilia, and positive serological findings. Definitive diagnosis of strongyloidiasis is generally made by the detection of larvae in the stool. Sputum examination may rarely be used to identify organisms in cases of hyperinfection. Agar tracking (detection of larval tracks on agar culture plates) has been shown to be more sensitive than the conventional stool examination. However, agar tracking is usually unavailable on a routine basis in clinical microbiology laboratories. Immunodiagnostic tests for strongyloidiasis are indicated when the infection is suspected and the organism cannot be demonstrated by repeated examinations of stool. Enzyme immunoassay (EIA) is currently recommended because of its greater sensitivity (90%). Antibody test results cannot be used to differentiate between the past and current infection. In disseminated cases of strongyloidiasis, larvae can be detected in sputum by simple wet-mount in fluid from a bronchoalveolar lavage (BAL).

X-ray

X rays can be helpful in the diagnosis of strongyloidiasis. Radiographic findings are variable, depending upon the stage and extent of infection which includes pulmonary infiltrates, when present, may be alveolar or interstitial, diffuse or focal, uni- or bilateral. Lung consolidation, occasional cavitation, and even abscess formation can also be found. Plain abdominal radiographs and contrast studies can reveal worm masses in bowel loops. Chest radiographs are explained by pulmonary migration of the parasites and by different types of bacterial super-infection, particularly gram-negative bacilli.

CT

There are no specific CT findings associated with strongyloidiasis. However, in cases of abdominal obstruction due to worm burden, CT can demonstrate collapsed loops of the bowel distally and radial distribution of several dilated, fluid-filled bowel loops.

MRI

There are no specific MRI findings associated with strongyloidiasis.

Ultrasound

There are no specific ultrasound findings associated with strongyloidiasis.

Other Imaging Findings

There are no other specific imaging findings associated with strongyloidiasis infection.

Other diagnostic tests

Upper and lower GI endoscopy, skin biopsy, and BAL fluid examination are some other diagnostic tests that are employed in diagnosing strongyloidiasis when there is a negative stool exam.

Treatment

Medical Therapy

Ivermectin, thiabendazole, and albendazole are the most effective medicines for treating strongyloidiasis infection. Ivermectin is the drug of choice, and albendazole is considered the least effective. Thiabendazole is not generally used in the U.S. due to adverse events, but it is still used in other countries. All patients with strongyloidiasis (even asymptomatic patients) require treatment. Complete obstruction with inadequate decompression, lack of response within an interval of 24-48 hrs, volvulus, intussusception, or perforation should be managed surgically.

Surgery

Strongyloidiasis is usually managed with medical therapy. However, surgery may be indicated when medical management fails or complications arise.

Primary Prevention

The prevention of strongyloidiasis is best achieved through improvements in personal hygiene and environmental sanitation.

Secondary Prevention

Secondary preventive measures of strongyloidiasis are similar to primary preventive measures.

References

Template:WH Template:WS